Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Pediatric Rheumatology
Published in: Pediatric Rheumatology 1/2020

Open Access 01-12-2020 | Anakinra | Case Report

Successful treatment of refractory hyperferritinemic syndromes with canakinumab: a report of two cases

Authors: Riccardo Papa, Valentina Natoli, Roberta Caorsi, Francesca Minoia, Marco Gattorno, Angelo Ravelli

Published in: Pediatric Rheumatology | Issue 1/2020

Login to get access

Abstract

Background

Hyperferritinemic syndromes are systemic inflammatory disorders characterized by a dysfunctional immune response, which leads to excessive activation of the monocyte-macrophage system with hypercytokinemia and may pursue a rapidly fatal course.

Case presentation

We describe two patients of 11 and 9 years of age with hyperferritinemic syndromes, one with impending macrophage activation syndrome (MAS) and one with overt MAS, who were refractory or intolerant to conventional therapies, but improved dramatically with canakinumab.

Conclusions

Our report indicates that canakinumab may be efficacious in the management of hyperferritinemic syndromes, including MAS.
Literature
1.
Schulert GS, Canna SW. Convergent pathways of the hyperferritinemic syndromes. Int Immunol. 2018;30:195–203.CrossRef
2.
Al-Samkari H, Berliner N. Hemophagocytic Lymphohistiocytosis. Annu Rev Pathol. 2018;13:27–49.CrossRef
3.
Ravelli A, Davì S, Minoia F, Martini A, Cron RQ. Macrophage activation syndrome. Hematol Oncol Clin North Am. 2015;29:927–41.CrossRef
4.
Crayne CB, Albeituni S, Nichols KE, Cron RQ. The immunology of macrophage activation syndrome. Front Immunol. 2019;10:119.CrossRef
5.
Lee JJY, Schneider R. Systemic juvenile idiopathic arthritis. Pediatr Clin N Am. 2018;65:691–709.CrossRef
6.
Nirmala N, Grom A, Gram H. Biomarkers in systemic juvenile idiopathic arthritis: a comparison with biomarkers in Cryopyrin associated periodic syndromes. Curr Opin Rheumatol. 2014;26:545–52.CrossRef
7.
Henter J-I, Horne A, Aricó M, Egeler M, Filipovich AH, Imashuku S, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124–31.CrossRef
8.
Ravelli A, Magni-Manzoni S, Pistorio A, Besana C, Foti T, Ruperto N, et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr. 2005;146:598–604.CrossRef
9.
Ravelli A, Minoia F, Davì S, Horne AC, Bovis F, Pistorio A, et al. Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European league against rheumatism/American College of Rheumatology/Paediatric rheumatology international trials organisation collaboration. Arthritis Rheumatol. 2016;68:566–76.CrossRef
10.
Minoia F, Bovis F, Davì S, Horne AC, Fischbach M, Frosch M, et al. Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Ann Rheum Dis. 2019;78:1357–62.CrossRef
11.
Nigrovic PA, Mannion M, Prince FHM, Zeft A, Rabinovich CE, van Rossum MAJ, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011;63:545–55.CrossRef
12.
Miettunen PM, Narendran A, Jayanthan A, Behrens EM, Cron RQ. Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology (Oxford). 2011;50:417–9.CrossRef
13.
Kelly A, Ramanan AV. A case of macrophage activation syndrome successfully treated with anakinra. Nat Clin Pract Rheumatol. 2008;4:615–20.CrossRef
14.
Durand M, Troyanov Y, Laflamme P, Gregoire G. Macrophage activation syndrome treated with anakinra. J Rheumatol. 2010;37:879–80.CrossRef
15.
Bruck N, Suttorp M, Kabus M, Heubner G, Gahr M, Pessler F. Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids. J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis. 2011;17:23–7.
16.
Kahn PJ, Cron RQ. Higher-dose Anakinra is effective in a case of medically refractory macrophage activation syndrome. J Rheumatol. 2013;40:743–4.CrossRef
17.
Record JL, Beukelman T, Cron RQ. Combination therapy of abatacept and anakinra in children with refractory systemic juvenile idiopathic arthritis: a retrospective case series. J Rheumatol. 2011;38:180–1.CrossRef
18.
Ravelli A, Grom AA, Behrens EM, Cron RQ. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun. 2012;13:289–98.CrossRef
19.
Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, et al. Two randomized trials of Canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2396–406.CrossRef
20.
Grom AA, Ilowite NT, Pascual V, Brunner HI, Martini A, Lovell D, et al. Rate and clinical presentation of macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with Canakinumab. Arthritis Rheumatol Hoboken NJ. 2016;68:218–28.CrossRef
21.
Grom AA, Horne A, De Benedetti F. Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol. 2016;12:259–68.CrossRef
22.
Kostik M, Snegireva L, Dubko M, Masalova V, Likhacheva T, Kornishina T, et al. A98: rescue treatment by increased doses of IL-1 inhibitors for macrophage activation syndrome in children with systemic juvenile idiopathic arthritis [abstract]. Arthritis Rheumatol. 2014;66:S133.CrossRef
23.
Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390–2.PubMed
24.
Möller JC, Paul D, Ganser G, Range U, Gahr M, Kelsch R, et al. IL10 promoter polymorphisms are associated with systemic onset juvenile idiopathic arthritis (SoJIA). Clin Exp Rheumatol. 2010;28:912–8.PubMed
25.
Krebs P, Crozat K, Popkin D, Oldstone MB, Beutler B. Disruption of MyD88 signaling suppresses hemophagocytic lymphohistiocytosis in mice. Blood. 2011;117:6582–8.CrossRef
26.
Hayashi K, Jin Z, Onoda S, Joko H, Teramoto N, Ohara N, et al. Rabbit model for human EBV-associated hemophagocytic syndrome (HPS): sequential autopsy analysis and characterization of IL-2-dependent cell lines established from herpesvirus papio-induced fatal rabbit lymphoproliferative diseases with HPS. Am J Pathol. 2003;162:1721–36.CrossRef
27.
Hsieh W-C, Chang Y, Hsu M-C, Lan B-S, Hsiao G-C, Chuang H-C, et al. Emergence of anti-red blood cell antibodies triggers red cell phagocytosis by activated macrophages in a rabbit model of Epstein-Barr virus-associated hemophagocytic syndrome. Am J Pathol. 2007;170:1629–39.CrossRef
28.
Tucker LB, Lamot L, Niemirtz I, Chung BK, Cabral DA, Houghton K, et al. Complexity in unclassified autoinflammatory disease: a case report illustrating the potential for disease arising from the allelic burden of multiple variants. Pediatr Rheumatol Online J. 2019;17:70–7.CrossRef
Metadata
Title
Successful treatment of refractory hyperferritinemic syndromes with canakinumab: a report of two cases
Authors
Riccardo Papa
Valentina Natoli
Roberta Caorsi
Francesca Minoia
Marco Gattorno
Angelo Ravelli
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Pediatric Rheumatology / Issue 1/2020
Electronic ISSN: 1546-0096
DOI
https://doi.org/10.1186/s12969-020-00450-9

Other articles of this Issue 1/2020

Pediatric Rheumatology 1/2020 Go to the issue

Research article

Spectrum of paediatric rheumatic disorders at a tertiary hospital in Tanzania

Commentary

The paediatric global musculoskeletal task force - ‘towards better MSK health for all’

Research article

Patients with enthesitis related arthritis show similar monocyte function pattern as seen in adult axial spondyloarthropathy

Research article

C-type natriuretic peptide stimulates osteoblastic proliferation and collagen-X expression but suppresses fibroblast growth factor-23 expression in vitro

Case Report

Importance of pediatric rheumatologists and transitional care for juvenile idiopathic arthritis-associated uveitis: a retrospective series of 9 cases

Case Report

Neonatal Kawasaki disease with multiple arterial aneurysms: a case report